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Although many studies have been conducted to investigate the relation between anthropometry and the risk of
ovarian cancer, their results have been inconsistent. The Netherlands Cohort Study on Diet and Cancer was
initiated in 1986. A self-administered questionnaire on dietary habits and other risk factors for cancer was
completed by 62,573 women. Follow-up for cancer was implemented by annual record linkages with the
Netherlands Cancer Registry. After 7.3 years of follow-up, 172 incident cases of invasive epithelial ovarian cancer
were available for analysis. Multivariate analysis yielded a rate ratio of ovarian cancer for women with adult height
of more than 175 cm, compared with those with height of less than or equal to 160 cm, of 2.17 (95% confidence
interval: 1.14, 4.13; p trend = 0.01). The rate ratio for women with a body mass index of more than 30 kg/m2 was
1.69 (95% confidence interval: 1.00, 2.86), compared with women with a Quetelet index of less than 25 kg/m2,
with p trend = 0.06. Rate ratios for weight and body mass index at age 20 years were nonsignificantly increased
in the intermediate categories. These data support a positive association between height (and to a lesser extent
body mass) and ovarian cancer risk in this population of postmenopausal women.
body constitution; body height; body mass index; body weight; cohort studies; ovarian neoplasms
Abbreviations: CI, confidence interval; RR, rate ratio.
Obesity has been found to be an important risk factor for
many cancers. In the European Union, 5 percent of all
cancers have been attributed to excess weight (1). The
evidence for a consistent association with obesity is stron-
gest for breast, colorectal, endometrial, gallbladder, kidney,
and prostate cancer (1, 2).
An American Cancer Society study linked obesity to
increased risk of ovarian cancer (3, 4). This relation is plau-
sible, because several clinical conditions (e.g., polycystic
ovarian syndrome, infertility, and so on) have been linked to
both obesity and ovarian cancer (5–9). However, the results
of other epidemiologic studies evaluating the relation
between obesity and ovarian cancer have been inconsistent.
Comparing their results is difficult because different
methods were used, some studies using a clinical diagnosis
of obesity from medical discharge registries as the exposure
variable (10, 11) and other studies comparing mean values or
presenting only the results for the top exposure category
compared with the reference category.
The results of hospital-based case-control studies have
been heterogeneous (12–20). These studies might suffer
from selection bias, however, because it cannot be excluded
that obesity was overrepresented in the control group (21,
22). Almost all population-based case-control studies have
reported a positive relation (although not always statistically
significant) between body mass and ovarian cancer risk (22–
34). Very few prospective studies have been conducted (3,
10, 11, 35–37). Most of them showed a small positive effect
of body mass on the risk of ovarian cancer. Only two studies
were able to control for confounding by other important risk
factors (36, 37). The Iowa Women’s Health Study cohort
found the rate ratio of the highest category to be only very
marginally elevated. Another anthropometric measurement,
waist/hip ratio, was positively correlated with ovarian cancer
(36). A recent nested case-control study within a multicenter
cohort study observed an inverse association (37).
The number of studies evaluating the relation between
height and ovarian cancer has been much smaller. Some
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case-control studies reported a greater average height among
cases than among controls (13, 18), although the difference
was not statistically significant. Some studies reported
elevated rate ratios for the highest categories, although again
the differences were not significant (31, 38, 39).
Considering the lack of evidence on this topic and the
heterogeneity of the published results, we decided to study
anthropometry in relation to ovarian cancer in a prospective
cohort study, allowing adjustment for the main potential
confounders. We therefore examined the association of
height and (relative) weight with ovarian cancer in the Neth-
erlands Cohort Study on Diet and Cancer, which provides
information on many potential confounders. We also evalu-
ated whether dynamic anthropometric measures, such as
(relative) weight gain during adulthood, are predictors of
ovarian cancer risk.
MATERIALS AND METHODS
The cohort
The Netherlands Cohort Study on Diet and Cancer started
in September 1986 when 62,573 Dutch women aged 55–69
years were enrolled in the cohort. All women were presumed
to be postmenopausal. At baseline, cohort members
completed a self-administered questionnaire on usual dietary
intake and potential confounders, such as reproductive
history, anthropometry, smoking habits, education, use of
hormones, and family history of cancer. Data processing and
analysis in the Cohort Study are based on the case-cohort
approach; the cases are enumerated for the entire cohort
(numerator information on incidence rates), while the accu-
mulated person-years of the entire cohort are estimated using
a subcohort sample (providing the denominator informa-
tion). Following this approach, a subcohort of 1,812 women
(2.9 percent of the total cohort) was sampled randomly from
the cohort after the baseline exposure measurement. The size
of the subcohort was based on calculations that have been
described more extensively in a previous publication (40).
Prevalent cancer cases (other than skin cancer) were
excluded from the subcohort, with the result that 1,716
women remained in this group. The subcohort has been
followed up biennially by mail for vital status information.
The vital status of subcohort members who did not respond
to the letter was completed by contacting the municipal
register. Incident cancer cases occurring in the entire cohort
were identified by record linkage to the Netherlands Cancer
Registry and the Netherlands Pathology Registry (PALGA).
Further details on the design of the Netherlands Cohort
Study on Diet and Cancer and the method of cancer follow-
up can be found in previous publications (40, 41).
The present analysis is restricted to cancer incidence in the
7.3-year follow-up period from September 1986 to
December 1993. The completeness of cancer follow-up was
estimated to be at least 96 percent (42), and no subcohort
members were lost to follow-up. After a follow-up period of
7.3 years, 202 incident, microscopically confirmed, primary
ovarian carcinomas were detected. After the exclusion of
nonepithelial tumors (n = 14) and borderline invasive tumors
(n = 2), 186 cases remained available. Women in the subco-
hort who had reported at baseline to have undergone an
oophorectomy (n = 16) were excluded, leaving 1,700 subco-
hort members for analysis.
Questionnaire data
Self-reported information on height (in cm) and weight (in
kg) at baseline, as well as weight at age 20 years (in kg), was
obtained from the questionnaire. Questionnaire data of all
cases and subcohort members were key entered twice and
processed in a manner blinded with respect to case/subcohort
status to minimize observer bias in the coding and interpre-
tation of data. The baseline body mass index and the body
mass index at age 20 years were calculated using baseline
weight and weight at age 20 years, respectively, divided by
height at baseline squared (kg/m2). Body mass index was
classified into the categories recommended by the National
Institutes of Health (43). Because very few women in the
subcohort fell into the three highest National Institutes of
Health categories (30.0–34.9, 35.0–39.9, and ≥40.0 kg/m2),
these categories were combined. The following categories
were thus used for body mass index: normal (≤24.9 kg/m2),
overweight (25–29.9 kg/m2), and obese (≥30 kg/m2). The
change in body mass index from age 20 years was calculated
as the body mass index at baseline minus the body mass
index at age 20 years.
Women with incomplete anthropometric data were
excluded, leaving 172 cases and 1,636 subcohort members
for analysis. The analysis of weight at age 20 years was
based on 152 cases and 1,477 subcohort members with
complete data.
Data analysis
The mean values of the anthropometric variables were
compared between cases and subcohort members. Other
factors were considered as confounders if they were associ-
ated with ovarian cancer risk, if they were clearly associated
with the anthropometric variables, and if rate ratios changed
by more than 10 percent after adjustment. The confounders
considered were age (continuous), use of oral contraceptives
(ever vs. never), parity (no children, one or two children, or
three or more children), use of postmenopausal hormones
(ever vs. never), hysterectomy (yes or no), and family history
of breast and/or ovarian cancer (yes or no). Family history
was considered positive if breast and/or ovarian cancer was
reported in a first-degree relative, that is, mother, sister, or
daughter.
Incidence rate ratios and corresponding 95 percent confi-
dence intervals for ovarian cancer were estimated in the
age-adjusted and multivariate case-cohort analyses with
categorized and continuous anthropometric variables, using
exponentially distributed failure time regression models (44)
processed with the Stata statistical software package (Stata
Corporation, College Station, Texas). Standard errors were
estimated using the robust Hubert-White sandwich estimator
to account for additional variance introduced by sampling
from the cohort. This method is equivalent to the variance-
covariance estimator presented by Barlow (45). Tests for
dose-response trends in the risk of ovarian cancer were
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assessed by fitting ordinal exposure variables as continuous
terms and performing likelihood-ratio tests between regres-
sion models with and without these variables. Two-sided p
values are reported throughout the paper. Because preclin-
ical disease might influence weight, we repeated the anal-
yses for weight and body mass after excluding cases
occurring in the first year of follow-up.
RESULTS
A total of 172 cases with ovarian cancer were available for
analysis with complete anthropometric data. Of these 172
cases, 35 percent had a histologic diagnosis of serous carci-
noma, 12 percent had endometrioid carcinoma, 11 percent
had mucinous carcinoma, and 4 percent had clear cell carci-
noma, while 35 percent had a histologic diagnosis of adeno-
carcinoma not otherwise specified, and the histology of 2
percent was unspecified.
Table 1 lists the anthropometric variables for cases and
subcohort members. The mean height and weight differed
between cases and subcohort members, in that cases were
both taller and heavier. The difference in body mass index
between cases and subcohort members was not great. Cases
were also somewhat heavier than subcohort members at age
20 years. A comparison of subcohort members whose infor-
mation on weight at age 20 years was missing with those
who did report their weight at age 20 years yielded no signif-
icant differences in mean height, baseline weight, and body
mass index (data not shown).
Table 1 also shows some potentially confounding vari-
ables. Fewer cases than subcohort members reported ever
having used oral contraceptives (16.6 percent vs. 24.8
percent), fewer cases had children (73.7 percent vs. 82.5
percent), and fewer cases reported using postmenopausal
hormone therapy (8.1 percent vs. 12.3 percent). No major
differences were observed between cases and subcohort
members with respect to hysterectomy and family history of
breast and/or ovarian cancer. Because use of oral contracep-
tives, parity, and use of postmenopausal hormone therapy
were associated with the risk of ovarian cancer and changed
the risk estimate of one or more anthropometric variables,
these three variables were considered as confounders in the
further multivariate analyses.
Table 2 shows age-adjusted and multivariate-adjusted rate
ratios of ovarian cancer for height, baseline weight, and body
mass index at baseline. Height was positively correlated with
the risk of ovarian cancer in both the univariate and multi-
variate analyses (p trend = 0.01). Weight was also positively
associated with the risk of ovarian cancer but not signifi-
cantly so (p trend = 0.18). Women who were obese at base-
line (body mass index, ≥30 kg/m2) had an increased risk of
ovarian cancer compared with women who had a normal
body mass (rate ratio (RR) = 1.69, 95 percent confidence
interval (CI): 1.00, 2.86; p trend = 0.06).
Rate ratios for weight and body mass index at age 20 years
are shown in table 3. The intermediate weight category at
age 20 years showed the highest rate ratio of 1.79 compared
with the lowest category, although the difference was not
statistically significant (95 percent CI: 0.86, 3.72). The rate
ratio of the highest category was only marginally elevated
(RR = 1.11, 95 percent CI: 0.53, 2.32). Results for body mass
index at age 20 years were comparable: an elevated rate ratio
in the intermediate category (RR = 1.50, 95 percent CI: 0.89,
TABLE 1.   Anthropometric variables and potential confounders in ovarian cancer cases and 
subcohort members, Netherlands Cohort Study on Diet and Cancer, 1986–1993
* Based on 152 cases and 1,477 subcohort members.
† Family history was considered positive, when breast and/or ovarian cancer was reported in a
first-degree relative, that is, mother, sister, or daughter.
Cases 
(n = 172)
Subcohort members 
(n = 1,636)
Mean  Standard deviation Mean
Standard 
deviation
Anthropometric variables
Height at baseline (cm) 166.4  6.4 165.1  6.2
Weight at baseline (kg) 70.2  10.5 68.6  10.2
Body mass index at baseline (kg/m2) 25.3  3.5 25.2  3.5
Weight at age 20 years (kg)* 59.0  7.1 58.5  7.9
Body mass index at age 20 years (kg/m2)* 21.3  2.1 21.5  2.7
Potentially confounding variables
Age at baseline (years) 62.1  4.3 61.5  4.3
Ever use of oral contraceptives (%) 16.6 24.8
Parity (% ever having a liveborn child) 73.7 82.5
Ever use of postmenopausal hormone therapy (%) 8.1 12.3
Hysterectomy (%) 5.2 6.5
Family history of breast and/or ovarian cancer (%)† 8.7 8.4
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2.51) and a decreased risk in the highest category (RR =
0.79, 95 percent CI: 0.48, 1.32).
The results for change in weight and body mass index
between age 20 years and baseline are shown in table 4.
Weight change since age 20 years (adjusted for weight at age
20 years, height, and confounders) was positively associated
with an increased risk, although the difference was not statis-
tically significant. The rate ratio for women who had a
weight gain of 25 kg or more was 1.72 (95 percent CI: 0.72,
4.10) compared with women who had no weight change (p
trend = 0.10). Change in body mass (adjusted for body mass
at age 20 years) was not associated with the risk of ovarian
cancer (p trend = 0.64).
Rate ratios for weight and body mass after exclusion of
cases in the first year are presented in table 5. The rate ratios
for weight were lower than in the analysis with all cases. The
p trend was 0.33. The rate ratios for body mass index were
slightly lower than in the analysis with all cases. Women
who had a body mass index of 30 kg/m2 or higher had a rate
ratio of 1.62 (95 percent CI: 0.94, 2.80) compared with
women who had a body mass index lower than 25.
DISCUSSION
This cohort study, with a relatively large series of cases,
found a significant positive association between self-reported
height and ovarian cancer incidence after controlling for
several potential confounders. A positive but nonsignificant
association with ovarian cancer was observed for weight and
body mass index at baseline. Weight and body mass index at
age 20 years were not consistently associated with increased
risk of ovarian cancer, nor was change in weight and body
mass index between age 20 years and baseline.
These results from the Netherlands Cohort Study on Diet
and Cancer are not likely to have been affected by selection
or information bias. Selection bias is unlikely given the high
TABLE 2.   Rate ratios and 95% confidence intervals for ovarian cancer according to anthropometric variables, Netherlands Cohort 
Study on Diet and Cancer, 1986–1993
* RR, rate ratio; CI, confidence interval. 
† Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), and ever use of
postmenopausal hormone therapy.
‡ Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), ever use of
postmenopausal hormones, and height.
Anthropometric variables Categorical 
mean
Age adjusted Multivariate adjusted
No. of cases/
no. of person-years 
in subcohort
RR* 95% CI*
No. of cases/ 
no. of person-years 
in subcohort
RR† 95% CI
Height at baseline (cm)
<160 155.7 28/1,977 1 Reference 23/1,905 1 Reference
160–164 161.9 36/3,050 0.83 0.50, 1.40 36/2,875 0.98 0.57, 1.70
165–169 166.8 47/3,770 0.89 0.55, 1.46 45/3,603 1.01 0.59, 1.71
170–174 171.4 39/1,957 1.45 0.87, 2.43 35/1,901 1.51 0.86, 2.65
≥175 176.7 22/820 1.98 1.09, 3.62 20/791 2.17 1.14, 4.13
p trend = 0.01 p trend = 0.01
Height continuous, 10-cm increments 1.45 1.11, 1.89 1.42 1.08, 1.87
Weight at baseline (kg)
<65 58.6 51/4,151 1 Reference 47/4,008 1 Reference‡
65–69 66.6 36/2,234 1.31 0.83, 2.04 33/2,212 1.25 0.77, 2.03
70–74 71.4 31/2,180 1.16 0.73, 1.85 31/2,129 1.23 0.76, 1.99
75–79 76.2 24/1,317 1.49 0.89, 2.49 23/1,253 1.54 0.89, 2.65
≥80 85.8 30/1,712 1.43 0.89, 2.30 28/1,632 1.32 0.78, 2.25
p trend = 0.10 p trend = 0.18
Weight continuous, 10- kg increments 1.17 1.01, 1.35 1.16 0.98, 1.37
Body mass index (kg/m2)
≤24.9 22.6 86/6,232 1 Reference 78/6,023 1 Reference
25–29.9 27.0 65/4,306 1.09 0.78, 1.53 61/4,089 1.21 0.84, 1.73
≥30 32.6 21/1,056 1.45 0.87, 2.41 20/962 1.69 1.00, 2.86
p trend = 0.20 p trend = 0.06
Body mass index continuous, 8-kg/m2 
increments 1.11 0.78, 1.57 1.25 0.88, 1.78
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level of follow-up of cases and subcohort person-years (42,
46). All of the anthropometric results were self-reported,
however, and misclassification of exposure is a potential
source of bias. Although several studies have reported high
correlations (r > 0.8) between self-reported and measured
anthropometric data (47–49), other publications reported
that, despite high correlations, weight tends to be underesti-
mated and height overestimated, thus leading to lower esti-
mates of body mass (50, 51). Mean values for the self-
reported height and weight, however, were comparable with
those of a representative sample of Dutch women 50–69
years of age measured in 1986 (52). The mean measured
height and weight of the latter group (n = 3,377) were 165.6
cm and 68.9 kg, respectively, compared with 165.1 cm and
68.6 kg for our subcohort of women from the Netherlands
Cohort Study on Diet and Cancer. Weight at age 20 years
was used to calculate body mass index at age 20 years, and
misclassification might have occurred because weight at age
20 years is difficult to remember. However, misclassifica-
tion is expected to be nondifferential, and therefore, a
possible effect on the risk estimates tends toward zero. Data
regarding weight (and body mass index) at age 20 years were
missing for 12 percent and 10 percent of the cases and the
subcohort members, respectively. Subcohort members with
and without information regarding weight at age 20 years did
not differ significantly in baseline anthropometric measures.
We were able to control for confounding by the most impor-
tant risk factors (7). However, all covariates were measured
at baseline only, and it is conceivable that use of postmeno-
pausal hormone therapy had changed since then.
Obesity may have hampered diagnostics, causing delay in
diagnosis, which would lower the risk estimates in the
highest weight category. It is also conceivable that preclin-
ical disease causes weight loss and may confound an associ-
ation with body weight (2).
The relation between height and the risk of ovarian cancer
has been studied in a few case-control studies. Two of these
studies reported that cases were slightly more than 1 cm
taller than controls, although the difference was not statisti-
cally significant (13, 18). This difference is in exact agree-
ment with the findings of the present study. Another case-
control study, however, reported no difference in mean
height between cases and controls (24). In Greece, women
with a height of 165 cm or more had a risk of 1.8 (95 percent
CI: 0.8, 3.9) compared with women with a height of 154 cm
or less (38). A more recent study in the same geographic
TABLE 3.   Rate ratios and 95% confidence intervals for ovarian cancer according to anthropometric variables at age 20 years, 
Netherlands Cohort Study on Diet and Cancer, 1986–1993
* RR, rate ratio; CI, confidence interval. 
† Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), and ever use of
postmenopausal hormone therapy.
‡ Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), ever use of
postmenopausal hormones, and height. 
Anthropometric variables Categorical 
mean
Age adjusted Multivariate adjusted
No. of cases/ 
no. of person-years
 in subcohort
RR* 95% CI*
No. of cases/
no. of person-years 
in subcohort
RR† 95% CI
Weight at age 20 years (kg)
<49 46.3 10/1,132 1 Reference 10/1,088 1 Reference‡
50–54 51.2 24/2,076 1.33 0.62, 2.84 22/1,996 1.15 0.53, 2.48
55–59 56.7 39/2,066 2.17 1.06, 4.45 34/1,978 1.79 0.86, 3.72
60–64 61.0 49/2,900 1.93 0.96, 3.90 46/2,780 1.55 0.77, 3.13
≥65 69.3 30/2,312 1.51 0.72, 3.17 28/2,196 1.11 0.53, 2.32
p trend = 0.19 p trend = 0.72
Weight at 20 years 
continuous, 10-kg 
increments 1.09 0.91, 1.32 0.99 0.81, 1.21
Body mass index at age 20 
years (kg/m2)
<20 18.4 43/3,043 1 Reference 40/2,941 1 Reference
20–20.9 20.5 29/1,453 1.39 0.84, 2.29 28/1,389 1.50 0.89, 2.51
21–22.9 22.0 50/3,236 1.09 0.71, 1.68 44/3,098 1.06 0.68, 1.67
≥23 24.8 30/2,753 0.78 0.48, 1.26 28/2,610 0.79 0.48, 1.32
p trend = 0.29 p trend = 0.30
Body mass index at 20 years 
continuous, 8-kg/m2 
increments 0.85 0.57, 1.27 0.85 0.56, 1.31
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location did show a much lower risk estimate: Women with
a height of 165 cm or more had a rate ratio of 1.13 (95
percent CI: 0.67, 1.90) compared with women with a height
of 159 cm or less (53). The observed difference in outcome
might be explained by the different reference category, but
also by cohort effects. Polychronopoulou et al. (53) did not
exclude an effect of height and suggested that the increasing
trend in ovarian cancer mortality in Greece could be caused
in part by the dramatic increase in adult height in that
country. Two case-control studies in China and Japan found
nonsignificantly increased risk estimates for the highest
category compared with the lowest: 1.3 (95 percent CI: 0.6,
3.1) and 1.4 (95 percent CI: 0.6, 3.0), respectively (31, 39).
Only one prospective study has provided results on the rela-
tion between height and risk of ovarian cancer (54). The
power of this study (only nine cases) was too small to yield
any meaningful results. A recent multicenter nested case-
control study reported some evidence of a direct association
of ovarian cancer and height in cancers diagnosed before the
age of 55 years (37), but precise rate ratios were not
published.
Height has been associated with several types of cancer,
especially breast cancer (55). Height as such does not cause
cancer but probably acts as a biomarker for some other expo-
sure (55). Suggested hypotheses include genetic factors,
calorie restriction in early life, and an increased exposure to
sex and growth hormones. Several investigators have noted
that height-cancer associations are strongest in birth cohorts
exposed to periods of food shortages during prepubertal
growth (56–59). This may also be a possible clue to the
apparent discrepancy in outcomes between the two Greek
studies (38, 53). Women in the Dutch cohort of the Nether-
lands Cohort Study on Diet and Cancer experienced the
economic crisis of the 1930s in their youth, as well as the
German occupation during the Second World War, including
particularly the famine in the winter of 1944 (60). Food
restriction during youth may restrict serum levels of insulin-
like growth factor I (61, 62), which inhibits apoptosis of
damaged cells and stimulates cell turnover and cell prolifer-
ation (63, 64). The link between height and increased risk of
ovarian cancer therefore does not seem implausible, and
TABLE 4.   Rate ratios and 95% confidence intervals for ovarian cancer according to change in weight and change in body mass 
index between age 20 years and baseline, Netherlands Cohort Study on Diet and Cancer, 1986–1993
* RR, rate ratio; CI, confidence interval.
† Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), and ever use of
postmenopausal hormone therapy.
‡ Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), ever use of
postmenopausal hormones, and height.
Anthropometric variables Categorical 
mean
Age adjusted Multivariate adjusted
No. of cases/ 
no. of person-years 
in subcohort
RR* 95% CI*
No. of cases/ 
no. of person-years 
in subcohort
RR† 95% CI
Weight change (kg)
–34–<0 –6.7 16/1,277 0.95 0.47, 1.92 14/1,229 1.01 0.46, 2.23
0–4.9 2.4 19/1,452 1 Reference 15/1,394 1 Reference‡
5–9.9 6.8 32/2,228 1.11 0.61, 2.02 30/2,134 1.32 0.68, 2.54
10–14.9 11.6 33/2,252 1.19 0.65, 2.16 32/2,150 1.42 0.74, 2.72
15–19.9 16.5 24/1,515 1.29 0.68, 2.45 24/1,465 1.57 0.78, 3.15
20–24.9 21.6 14/1,019 1.17 0.56, 2.47 14/975 1.48 0.67, 3.26
≥25 30.7 14/743 1.73 0.79, 3.77 11/692 1.72 0.72, 4.10
p trend = 0.14 p trend = 0.10
Weight change continuous, 10-kg 
increments 1.13 0.95, 1.34 1.15 0.95, 1.39
Body mass index change (kg/m2)
–13.4–<0 –2.4 18/1,339 1.03 0.54, 1.97 15/1,290 0.85 0.42, 1.73
0–1.9 1.2 28/1,966 1 Reference 25/1,886 1 Reference
2.0–3.9 3.1 38/2,493 1.02 0.61, 1.72 35/2,377 1.03 0.59, 1.80
4.0–5.9 4.9 29/2,137 0.91 0.53, 1.57 29/2,037 1.00 0.56, 1.76
6.0–7.9 6.9 22/1,368 1.06 0.57, 1.98 22/1,339 1.23 0.64, 2.36
8.0–9.9 8.8 10/701 1.01 0.46, 2.19 7/650 0.81 0.33, 1.97
≥10.0 12.3 7/480 0.98 0.40, 2.41 7/459 1.15 0.47, 2.84
p trend = 0.93 p trend = 0.64
Body mass index change continuous, 
8- kg/m2 increments 1.12 0.75, 1.66 1.28 0.86, 1.91
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insulin-like growth factor I must be considered as one of the
factors involved in this relation.
Although several studies have published results on the
relation between weight or body mass and the risk of ovarian
cancer, interpretation is hampered by differences in method-
ology and presentation of the results. A study by the Amer-
ican Cancer Society was the first to publish results on the
relation between anthropometric data and the risk of ovarian
cancer (3, 4). Women whose weight was 40 percent higher
than the mean (adjusted for age and height) had a rate ratio
of 1.63 compared with women of average weight. Several
case-control studies have reported a higher average weight
or body mass index among cases than among controls (18,
29) or reported a higher prevalence or increased rate ratio for
excess (relative) weight or clinical obesity among cases (12,
23, 25, 65). On the other hand, several other case-control
studies have reported lower average weight for cases than for
controls (13, 17, 18) or decreased rate ratios for the highest
category of (relative) weight (14, 15, 19, 66, 67).
As noted by Whittemore et al. (68) and Purdie et al. (22),
all these studies that found a negative or no association used
hospital-based controls (13–20). Selection bias has been
suggested as an explanation for the lack of association or the
negative associations found in hospital-based case-control
studies (21, 22). It was suggested that obese persons are
overrepresented in a series of hospital controls. Most case-
control studies, however, including almost all population-
based case-control studies, published a positive, albeit
moderate association between weight and/or body mass
index and the risk of ovarian cancer (22, 24, 26–28, 30, 31,
34). A few case-control studies reported no association or a
very small association (odds ratio ≤ 1.1): Two of these were
hospital based (16, 20), and two were population based (32,
39). A recent systematic review concluded that there is a
small-to-moderate positive relation between high body mass
index and the occurrence of ovarian cancer (22). Overall, the
hospital-based case-control studies observed no relation
(summary RR = 1.1, 95 percent CI: 0.9, 1.2), while the popu-
lation-based case-control studies yielded positive relations
(summary RR = 1.4, 95 percent CI: 1.2, 1.6) (22). Since the
study by the American Cancer Society, only a few prospec-
tive cohort studies have published results with respect to the
relation between weight or body mass index and ovarian
cancer risk. Törnberg and Carstensen (35) analyzed the risk
of increasing body mass index and found a positive associa-
tion in women below the age of 55 years (RR = 1.66 for body
mass index of 28 or higher compared with body mass index
below 22) but no association in women who were more than
55 years of age. These rate ratios were not adjusted for the
major potential confounders. Moller et al. (10) and Wolk et
al. (11) studied the incidence of ovarian cancer in women
who had been recorded in the hospital discharge registry
with a diagnosis of obesity (International Classification of
Diseases, Ninth Revision, code 277) and compared the
observed incidence rates with the expected rates based on the
general population. Moller et al. found a small and statisti-
TABLE 5.   Rate ratios and 95% confidence intervals for ovarian cancer according to anthropometric variables at baseline after 
exclusion of cases diagnosed during the first year of follow-up, Netherlands Cohort Study on Diet and Cancer, 1986–1993
* RR, rate ratio; CI, confidence interval.
† Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), and ever use of
postmenopausal hormone therapy.
‡ Rate ratios adjusted for age at baseline, ever use of oral contraceptives, parity (no children, 1–2 children, or ≥3 children), ever use of
postmenopausal hormones, and height.
Anthropometric variables Categorical 
mean
Age adjusted Multivariate adjusted
No. of cases/ 
no. of person-years 
in subcohort
RR* 95% CI*
No. of cases/ 
no. of person-years 
in subcohort
RR† 95% CI
Weight at baseline (kg)
<65 58.6 50/4,150 1 Reference 44/3,963 1 Reference‡
65–69 66.6 33/2,233 1.22 0.77, 1.94 30/2,174 1.16 0.70, 1.91
70–74 71.4 30/2,179 1.15 0.72, 1.84 30/2,106 1.21 0.74, 1.97
75–79 76.2 22/1,317 1.39 0.82, 2.36 21/1,238 1.43 0.81, 2.51
≥80 85.8 25/1,711 1.21 0.73, 2.01 24/1,588 1.19 0.69, 2.07
p trend = 0.31 p trend = 0.33
Weight continuous, 10-kg 
increments 1.12 0.96, 1.31 1.13 0.95, 1.34
Body mass index (kg/m2)
≤24.9 22.6 82/6,229 1 Reference 74/6,020 1 Reference
25–29.9 27.0 60/4,305 1.06 0.75, 1.50 57/4,087 1.20 0.83, 1.73
≥30 32.6 18/1,056 1.30 0.76, 2.23 18/961 1.62 0.94, 2.80
p trend = 0.40 p trend = 0.09
Body mass index 
continuous, 8-kg/m2 
increments 1.00 0.95, 1.05 1.02 0.98, 1.07
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cally nonsignificant risk (RR = 1.1, 95 percent CI: 0.8, 1.4),
while Wolk et al. found a rate ratio of 1.2 (95 percent CI: 1.1,
1.5). These studies could not adjust for confounders. Mink et
al. (36) were able to adjust for confounders and found no
statistically significant association for women who had a
body mass index higher than 29.5 compared with those who
had a body mass index lower than 23.5 (RR = 1.1, 95 percent
CI: 0.64, 1.93). The waist/hip ratio, however, was signifi-
cantly increased in the highest quartile compared with the
lowest quartile (RR = 1.92, 95 percent CI: 1.03, 3.60).
Overall, Purdie et al. (22) calculated a summary rate ratio of
1.2 (95 percent CI: 1.1, 1.3) for the cohort studies. These
results are in agreement with our findings.
The review by Purdie et al. did not include the study by
Lukanova et al. (37). In a multicenter nested case-control
study with 122 cases, they observed an inverse association
between increasing weight and risk of ovarian cancer. The
highest body mass index category (≥28.4 kg/m2) had a multi-
variate-adjusted relative risk of 0.46 compared with women
who had a body mass below 23.1. The age at recruitment in
this multicenter cohort was lower than in our cohort, and the
mean age at diagnosis was 59.4 years (compared with 62.1
years in our study). This means that a considerable propor-
tion of the cases must have been premenopausal at diagnosis,
and that the measured weight and body mass reflected
mainly premenopausal exposure.
As regards the etiology of ovarian cancer, several hypoth-
eses have been put forward. Fathalla (69) and Casagrande et
al. (23) have proposed the “incessant ovulation” hypothesis,
assuming that ovulation causes trauma to the ovarian epithe-
lium and that the higher the number of ovulations the greater
the risk of ovarian cancer. Cramer and Welch (70) suggested
that excessive amounts of gonadotropins stimulate ovarian
carcinogenesis. A more recent hypothesis by Risch (71)
suggests that high serum levels of androgens increase the
risk of ovarian cancer, while progestagens protect against
ovarian cancer.
Obesity has multiple effects on the hormonal status of pre-
and postmenopausal women. In premenopausal women, it
lowers sex hormone-binding globulin and increases the
serum levels of insulin-like growth factor I, but it does not
influence levels of estrogens and androgens significantly,
because the ovaries produce more steroids than the periph-
eral fat tissue (2, 72). In postmenopausal women, the levels
of estrogens and androgens are increased because the main
production is by peripheral fat tissue, while serum levels of
free progestagens are decreased (2). According to the
hypothesis by Risch this would predict a positive relation
between weight or body mass and the risk of ovarian cancer
in the postmenopausal period.
Only a limited number of case-control studies have
considered the influence of weight (or body mass index) at a
young adult age. Purdie et al. (22) reported little deviation
from zero across the range of body mass index at age 20
years. Farrow et al. (26) reported an increasing trend for
body mass index according to categories at age 30 years (p <
0.05). Mori et al. (31) reported an increased risk for women
heavier than 55 kg compared with women lighter than 45 kg
(odds ratio = 1.52, 95 percent CI: 0.78, 2.96). Our study
found no consistent increasing trend. The rate ratio was
nonsignificantly decreased in the highest category of body
mass index at age 20 years, while the rate ratio in the second
category was nonsignificantly increased. Purdie et al. (22)
reported a significantly elevated risk for the highest category
of change in weight since age 20 years. This observation was
not confirmed in our study. Clinical obesity (>30 kg/m2) in
the fertile age is known to increase the frequency of anovu-
latory menstrual cycles (73). The Nurses’ Health Study
found the risk of ovulatory infertility to be increased in
women with a body mass index less than 20 or greater than
24 (74). According to the theory by Fathalla (69), fewer
ovulatory cycles would decrease the risk of ovarian cancer.
As regards weight and body mass index at age 20 years, we
observed that the risks were smallest in the lowest and the
highest categories (although the differences were not statisti-
cally significant). According to Fathalla’s theory, this is in
agreement with the results of the Nurses’ Health Study.
The findings of the present prospective study support a
positive association between height (and to a lesser extent
weight) and ovarian cancer risk in this population of post-
menopausal women. Confirmation of these results in other
well-designed prospective studies is warranted, while the
relation with body mass at age 20 years and weight gain
since then needs further research.
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